Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.5%. By the end of trading, Regeneron Pharmaceuticals fell $5.90 (-3.2%) to $176.63 on heavy volume. Throughout the day, 1.6 million shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 841,800 shares. The stock ranged in price between $169.97-$176.80 after having opened the day at $175 as compared to the previous trading day's close of $182.53. Other companies within the Drugs industry that declined today were: Aoxing Pharmaceutical Company ( AXN), down 10%, Venaxis ( APPY), down 9.6%, Neostem ( NBS), down 7.1%, and NuPathe ( PATH), down 6.5%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $17.11 billion and is part of the health care sector. The company has a P/E ratio of 91.9, above the S&P 500 P/E ratio of 17.7. Shares are up 5.8% year to date as of the close of trading on Monday. Currently there are nine analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Cell Therapeutics ( CTIC), up 25.4%, Pacific Biosciences of California ( PACB), up 17.8%, Theratechnologies ( THER), up 15.8%, and Threshold Pharmaceuticals ( THLD), up 14.3%, were all gainers within the drugs industry with Vertex Pharmaceuticals ( VRTX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

HOLIDAY SPECIAL: Let Jim Cramer show you every trade he is making in his $2.5 Million portfolio. Join now for 14-days FREE. Sign up today to get e-mail alerts before every trade.